Keywords
cardiovascular complications
COVID-19
treatment
SARS-CoV-2
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the relationship between medication treatment and COVID-19 vaccines and the aggravation of cardiovascular complications. Methods: This is an integrative review conducted between August and November 2023. The databases used were the Coordination for the Improvement of Higher Education Personnel (CAPES), the National Library of Medicine, and the National Institutes of Health (PUBMED), and the Virtual Health Library (BVS). The descriptors used were "Heart Diseases", "Cardiovascular complications", "COVID-19", "Treatment" and "SARS-CoV-2" with the Boolean operator "AND." Review studies were excluded, and articles written in English and published between 2020 and 2023 were included. Results: Out of the 19 articles studied, 7 addressed medication treatment, which resulted in clinical improvement and increased survival time. The remaining 12 articles related to vaccines showed that the risk of cardiovascular complications is rare, with a higher frequency in young males. Final considerations: There were no significant occurrences of cardiovascular complications in patients who underwent medication treatment or received the vaccine for the disease, both of which are essential in combating the illness.
References
BIKDELI B, et al. Intermediate-Dose versus Standard-Dose Prophylactic: Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022; 122: 131-141.
CASARIN F, et al. AB1348 PERICARDITIS AFTER COVID-19 VACCINATION: a case series. Scientific Abstracts, 2023; 82: 1905.
CORRAO G, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in lombardy, italy. Bmc Infectious Diseases, 2022; 22: 844.
DEFTEREOS S, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. Jama Network Open, 2020; 3(6): e2013136.
FADAH K, et al. Acute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult. Cureus, 2023; 12: e02929.
FANG E, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction And Targeted Therapy, 2023; 7: 94.1.
FARAHMAND R, et al. Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects. The American Journal of Cardiology, 2022; 164: 123-130.
FOLEGATTI P, et al. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 2022; 40: 5248-5262.
HAJJO R, et al. Shedding Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines, 2021; 9: 1186.
INJAC R, et al. Global pandemic vaccine development, production and distribution challenges for the world population. International Journal Of Risk & Safety In Medicine, 2022; 33: 235-248.
KARLSTAD Ø, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. Jama Cardiology, 2022; 7: 600.
KLOK F, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 2020; 191: 145-147.
KYAW H, et al. COVID-19 mRNA Vaccine-Associated Myocarditis. Cureus, 2022; 14(1): e21009.
LOPES R, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. Jama, 2021; 325: 254.
MAARSE B, et al. Effect of hydroxychloroquine on the cardiac ventricular repolarization: a randomized clinical trial. British Journal of Clinical Pharmacology, 2021; 88: 1054-1062.
MARSHALL M, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics. 2021; 148(3): e2021052478
NÚÑEZ-GIL I, et al. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international hope covid-19 (health outcome predictive evaluation for covid-19) registry. American Heart Journal, 2021; 237: 104-115.
OSTROWSKI S, et al. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Frontiers In Immunology, 2021; 12.
PATONE M, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation, 2022; 146: 743-754.
PRISMA. 2023. Disponível em: <http://www.prisma-statement.org/>. Acesso em: 8 nov. 2023.
SCHATZMAYR H. Novas perspectivas em vacinas virais. História, Ciências, Saúde-Manguinhos, 2003; 10: 655-669.
TAVARES C, et al. Alterações da ECA2 e Fatores de Risco para Gravidade da COVID-19 em Pacientes com Idade Avançada. Arquivos Brasileiros de Cardiologia, 2020; 115: 701-707.
WANG T, et al. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Annals Of Internal Medicine, 2023; 176: 515-523.
WITBERG G, et al. Myocarditis after COVID-19 Vaccination in a Large Health Care Organization. New England Journal of Medicine, 2021; 385: 2132-2139
YE X, et al. BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease. Journal of the American Heart Association, 2023; 12.